top of page
  • Jonathan Poyer

Biotech News & Notes from February - The End of Exclusivity Is Nigh....





Loss of exclusivity is a growing theme as Jefferies projects there will be $170 billion of branded product revenue lost by 2028 prompting urgency for M&A



  • Mei Pharma (MEIP) and Infinity Pharmaceuticals (INFI) announced a merger

  • Jounce Therapeutics (JNCE) and Redx Pharma (REDX LN) are merging

  • Graphite Bio (GRPH) and Talaris therapeutics (TALS) announced significant reductions in force and exploration of strategic alternatives



  • Celldex Therapeutics (CLDX) rallying on favorable updated Phase Ib Data with KIT

  • Nektar Therapeutics (NKTR) crashed ~50% on negative Phase 2 data for IL-2 conjugate rezpegaldesleukin

  • Fulcrum Therapeutics (FULC) cratered 55% on announcing FDA placed a clinical hold on FTX-6058

  • FDA drug approval for Travere Therapeutics' (TVTX) Filspari

  • FDA drug approval for Apellis Pharmaceuticals' (APLS) Syfovre (pegcetacoplan)

  • Frequency Therapeutics (FREQ) crashed >80% upon announcing the failure of a phase 2b trial in hearing loss and a subsequent 55% reduction in force.

  • Blueprint Medicines (BPMC) announced FDA placed a partial clinical hold on trial of BLU-222

  • G1 therapeutics (GTHX) stopped a Ph3 trial for trilaciclib

  • Sanofi (SNY) stopped a phase 3 trial of the lead candidate acquired in the $3.7 billion takeover of Principia.

  • Taysha (TSHA) announced additional trials for Giant Axonal Neuropathy



  • Blueprint Medicines (BPMC) and Roche (RHHBY) terminated the Gavreto collaboration agreement

  • Rubius therapeutics (RUBY) announced a dissolution plan

  • Sorrento therapeutics (SRNE) filed for Chapter 11 bankruptcy in Texas.

  • Merck (MRK), Bristol Myers (BMY) and Abbvie (ABBV) will all be losing their top selling drug(s) Keytruda, Revlimid and Humira, respectively

  • The third biotech IPO of 2023 just might be the charm as Structure therapeutics (GPCR) traded up 73% after debuting with an upsized offering of $160 million


19 views0 comments

Comments


bottom of page